Credits: Canva
Have you ever been in such a deep slip and ended up waking coughing? Chances are, you choked on your own saliva. Yes, it is very much possible. Saliva is a clear liquid produced by your salivary glands that play a crucial role in digestion and oral health. This is because it washes away bacteria and food particles. The body on an average produces about 1 to 2 litres of saliva daily, and a lot of it is swallowed unconsciously. However, when saliva does not flow smoothly down the throat, it can lead to choking, which can be uncomfortable.
Here's all that you need to know about what causes it, and how can you prevent it.
This happens when the muscles that are responsible for swallowing weaken or malfunction due to health issues and the symptoms may include:
Some of the common reasons include:
Acid reflux occurs when stomach acid travels back into the esophagus and mouth, irritating the esophagus and increasing saliva production to neutralize the acid. This buildup of saliva can lead to choking.
Acid reflux can be diagnosed via endoscopy or X-rays. Treatment includes antacids to reduce stomach acid.
When you are sleeping, some abnormal swallowing can occur during that time and it may cause saliva to pool in the mouth and flow into the lungs. This is what leads to choking. This condition is often linked to obstructive sleep apnea (OSA), which causes breathing to pause during sleep.
CPAP machines to provide continuous airflow
Oral mouth guards to keep the airway open
Growths in the throat, whether benign or cancerous, can narrow the esophagus and impede swallowing.
Treatment may involve surgery, radiation, or chemotherapy, depending on the nature of the growth.
Dentures can confuse the brain into perceiving them as food and it may trigger excess saliva production and cause choking. The best way to work this out is by consulting a dentist for proper fitting and adjustment of dentures.
Conditions like Parkinson’s disease and ALS can impair the nerves that control swallowing.
Doctors may prescribe medication to reduce saliva production or teach swallowing techniques.
Excessive alcohol consumption can relax throat muscles, allowing saliva to pool and cause choking.
Moderate alcohol intake and sleep with your head elevated.
Speaking continuously without pausing to swallow can lead to saliva entering the windpipe.
Take pauses to swallow while talking.
Thickened saliva or mucus due to allergies or infections can obstruct the throat, especially during sleep.
Antihistamines, cold medication, or antibiotics may be prescribed, depending on the underlying cause.
In case of sleep apnea, sleep with your head elevated or on your side. You can also try and avoid lying flat right after eating and eat smaller meals to prevent acid reflux. It is also important that you sip water throughout the day to clear any saliva buildup. In severe cases, use over-the-counter medicines for allergies or consult a healthcare provider.
Credit: Canva
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, affects millions of people worldwide. The lifelong condition commonly begins in adolescence or early adulthood and can require repeated hospital treatment, long-term immunosuppressive medication, and, in some cases, surgery.
Despite advances in treatment, many patients cycle through multiple therapies without achieving lasting disease control, impacting their lives and costing healthcare systems millions.
Now, a team of UK researchers from the Universities of Oxford, Newcastle, and Cambridge has identified an important driver of inflammatory bowel disease (IBD).
The findings, published in the New England Journal of Medicine, suggest that inflammatory bowel disease is not a single condition but a group of biologically distinct diseases driven by different underlying mechanisms.
"Understanding what drives the inflammation provides a clear explanation for disease in this group of people and opens the door to new treatments that target the autoantibodies themselves or cells that produce those autoantibodies," said Professor Holm Uhlig, a pediatric gastroenterologist and director of the Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford.
Also read: Alcohol Study Shelved By Trump Administration Published In Scientific Journal: What Did It Find?
The researchers analyzed more than 4,900 patients with IBD and discovered that:
Antibodies that block interleukin-10 (IL-10), a cell-to-cell messenger that normally acts as one of the body's key controls on inflammation, effectively remove the immune system's natural "brake" on inflammation, allowing inflammatory responses to continue unchecked.
The researchers found high levels of anti-IL-10 neutralizing autoantibodies in the blood of about 3.5% of IBD patients, including those with Crohn's disease and ulcerative colitis, but not in healthy individuals. This could equate to 15,000–20,000 people with IBD in the UK carrying these autoantibodies.
Read More: US FDA Approves First New Sunscreen Ingredient Since the 1990s
The researchers also found that the presence of these antibodies was strongly linked to carriage of a particular genetic variant known as HLA-DRB1*01:03.
The link between HLA-DRB1*01:03 and a severe form of inflammatory bowel disease was first identified by Oxford researchers 30 years ago.
The new findings show that people carrying this variant are far more likely to develop antibodies that block IL-10, helping explain how the gene contributes to disease.
The researchers say the findings support the development of a blood test to identify this subgroup of patients, helping clinicians move quickly toward more appropriate treatment.
As per the Centers for Disease Control and Prevention (CDC), IBD refers to a group of lifelong diseases that affect your intestines. The main types of IBD are ulcerative colitis and Crohn's disease.
Ulcerative colitis affects the large intestine, while Crohn’s disease can inflame any part of the digestive tract. Both are lifelong conditions of unknown cause that trigger abdominal pain, diarrhea and other complications, with no known cure.
Credit: Canva
With modern lifestyle changes, delayed childbearing, and other factors, infertility among Indians as young as 25 has become a looming public health concern for the country. However, the issue does not stop at the present.
A recent study published by The Menopause Society in their journal Menopause found that infertility may lead to earlier menopause, raising questions about the long-term reproductive health implications of this demographic shift.
Menopause is the final stage of a woman’s reproductive lifecycle, when menstruation stops, and she can no longer get pregnant. When the ovaries stop producing estrogen and progesterone, and a woman misses her period for 12 consecutive months, she has officially reached menopause.
Although menopause is a regular part of ageing, women typically reach menopause between 45 and 55 years of age. If menopause occurs before age 45, it is considered early menopause. If it occurs before 40, it is termed premature menopause – rarer than early menopause but involves the same causes, symptoms, and health risks.
While previous studies have been conducted to find a link between infertility and both early and premature menopause, they have had mixed results and did not consider the effect of different types of infertility; this study focuses on women with a history of primary infertility, women who have never achieved pregnancy, and have difficulty conceiving.
For the study, researchers examined the reproductive lifecycle of nearly 700 women in the U.S. – 461 with primary infertility and 530 without infertility – who were otherwise demographically similar (age, education, smoking status, etc.). It found that the 461 women had a 25% higher likelihood of reaching natural menopause about 1.2 years earlier than the 530.
Researchers also noted that women with underlying endometriosis as a cause of their infertility reached menopause between 40 and 44 years, much sooner than the national average of the United States, i.e., 52 years.
Possible explanations include accelerated ovarian ageing, reduced ovarian reserve, or the effects of endometriosis on ovarian function. But no matter the causes, the implications for women’s long-term health are substantial.
All women are born with a finite, predetermined number of eggs, which are sensitive to age, environmental toxins, medications, hormonal imbalances, and lifestyle factors. When exposed to such risk factors, especially over a long period of time, the DNA inside the eggs is altered, causing permanent genetic damage and reducing the egg quality and quantity.
As a core part of the reproductive process, any damage to the eggs directly affects reproductive health and, in turn, long-term systemic health.
Infertility impacts more than the ability to conceive and go through a pregnancy; it is often a sign of underlying health conditions and potential chronic illnesses, acting as a biomarker of increased all-cause mortality. Experiencing infertility itself increases a woman’s risk of developing cardiovascular disease, metabolic disorders, gynecologic cancers, etc., but reaching menopause early on top of that puts them at further health risk, adding osteoporosis and cognitive decline to the mix, along with the emotional distress and mental health challenges.
Indian women already reach menopause earlier than women in Western countries, with the average woman experiencing menopause at 46.2 years of age. With fertility rates dropping across the country, this study highlights just how critical it is to increase fertility awareness. Early screenings and regular fertility testing can help detect risks early and enable timely intervention, not only to combat the ongoing crisis but to ensure that women live healthy, fulfilling lives without impending morbidity.
Credit: AI Generated Image
A new oral GLP-1 medication has delivered encouraging results in a Phase 2b clinical trial for people living with type 2 diabetes.
According to AstraZeneca, its experimental tablet, elecoglipron, significantly lowered blood sugar levels and helped participants lose an average of 10.5% of their body weight after 26 weeks of treatment.
The findings were presented at the 2026 American Diabetes Association Scientific Sessions in New Orleans and published in The Lancet on June 8.
Elecoglipron joins a growing wave of GLP-1 therapies being developed as pills, offering an alternative to injectable drugs such as Ozempic, Wegovy, Zepbound, and Mounjaro.
The first oral GLP-1 treatment, Rybelsus from Novo Nordisk, received FDA approval in 2019 for adults with type 2 diabetes. Since then, oral options have continued to expand. In December 2025, the FDA approved a tablet version of Wegovy for weight management, while Eli Lilly’s oral obesity treatment, Foundayo, gained approval in April.
Independent experts say AstraZeneca’s results highlight the growing potential of non-injectable GLP-1 therapies for both diabetes and obesity treatment.
“It’s encouraging to see another oral medication demonstrating the benefits of GLP-1 therapy without requiring injections,” said Dr. Pouya Shafipour, a family and obesity medicine specialist at Providence Saint John’s Health Center in California.
Dr. Marilyn Tan, an endocrinologist and professor of medicine at Stanford University, noted that the rapidly expanding GLP-1 market could soon welcome another oral treatment option if elecoglipron succeeds in Phase 3 trials and ultimately secures FDA approval.
GLP-1 is a natural hormone produced in the intestines that regulates blood sugar, appetite, and digestion. Now, every time you eat, your body produces various hormones, including GLP-1. These are called post-nutrition hormones, and they help you absorb the energy you just consumed.
GLP-1 travels to your pancreas, prompting it to produce insulin. It also travels to the hypothalamus in your brain, which gives you the feeling of being full or satiated. GLP-1 pills imitate that hormone, thereby silencing the food chatter in the brain. Interestingly, for some people, this food chatter is really quiet, and for others it is an outburst. So with GLP-1, silencing this self-talk in the brain, people tend to lose their appetite and eventually weight.
However, it is important to note that losing weight includes not just fat but muscle as well. Losing too much muscle can lead to reduced strength and a shorter life span. Notably, records show that most people who start taking them stop them at 12 weeks; therefore, it is important for some but not for others.
The side effects of these pills include:
© 2024 Bennett, Coleman & Company Limited